Osteoclast

Osteoclast designates a specialised multinucleated bone-resorbing cell derived from monocyte-macrophage lineage that degrades bone matrix through acidification and proteolytic enzyme secretion, playing a central role in bone remodelling and calcium homeostasis. Osteoclast activity balances osteoblast-mediated bone formation, with dysregulation causing pathological bone loss. Excessive osteoclast activation contributes to osteoporosis, bone metastases, rheumatoid arthritis-related bone erosion, and other skeletal disorders.

The biopharmaceutical industry targets osteoclast pathways for treating bone diseases, with bisphosphonates inhibiting osteoclast function forming standard treatments for osteoporosis and metastatic bone disease. Denosumab, a monoclonal antibody targeting RANKL, blocks osteoclast differentiation and activation, reducing bone loss and preventing skeletal-related events in cancer. Drug development focuses on pathways regulating osteoclast formation, including RANK-RANKL signalling and cytokine-mediated activation. Safety considerations include oversuppression of bone turnover, hypocalcaemia, and rare complications such as osteonecrosis of the jaw. As understanding deepens regarding bone biology and immune-bone interactions, osteoclast-targeted therapies continue advancing to improve outcomes in osteoporosis, cancer-related bone disease, and inflammatory skeletal disorders.